Patents by Inventor Hongjun Zhang

Hongjun Zhang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compounds as indoleamine 2,3-dioxygenase inhibitors
    Patent number: 10538497
    Abstract: Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.
    Type: Grant
    Filed: December 12, 2016
    Date of Patent: January 21, 2020
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Yongxin Han, Abdelghani Achab, Purakkattle Biju, Yongqi Deng, Xavier Fradera, Liangqin Guo, Shuwen He, Joseph Kozlowski, Ravi Kurukulasuriya, Kun Liu, Meredeth Ann McGowan, Qinglin Pu, Nunzio Sciammetta, Hongjun Zhang, Hua Zhou
  • POSITRON EMISSION TOMOGRAPHY IMAGING SYSTEM
    Publication number: 20190331810
    Abstract: The present disclosure relates to systems and methods for heat transfer and cooling in PET. The system may include a gantry including a gantry forming a detection tunnel; a detector mounted to the gantry, and positioned in a circumference of the detection tunnel; a heat transfer device thermally coupled with the detector and configured to transfer heat generated by the detector; and a cooling device thermally coupled to the heat transfer device, and configured to cool the heat transfer device.
    Type: Application
    Filed: June 13, 2019
    Publication date: October 31, 2019
    Applicant: SHANGHAI UNITED IMAGING HEALTHCARE CO., LTD.
    Inventors: Hao YAN, Wei ZHANG, Huawei JIANG, Shigang SU, Miao LI, Hongjun ZHANG, Weiping LIU
  • Tricyclic compounds as inhibitors of mutant IDH enzymes
    Patent number: 10442819
    Abstract: The present invention is directed to tricyclic compounds of formula (I) which are inhibitors of one or more mutant IDH enzymes: (I). The present invention is also directed to uses of the tricyclic compounds described herein in the potential treatment or prevention of cancers in which one or more mutant IDH enzymes are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such cancers.
    Type: Grant
    Filed: December 1, 2015
    Date of Patent: October 15, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Christian Fischer, Stephane L. Bogen, Matthew L. Childers, Francesc Xavier Fradera Llinas, J. Michael Ellis, Sara Esposite, Qingmei Hong, Chunhui Huang, Alexander J. Kim, John W. Lampe, Michelle R. Machacek, Daniel R. McMasters, Ryan D. Otte, Dann L. Parker, Jr., Michael Reutershan, Nunzio Sciammetta, Pengcheng P. Shao, David L. Sloman, Feroze Ujjainwalla, Catherine White, Zhicai Wu, Yang Yu, Kake Zhao, Craig Gibeau, Tesfaye Biftu, Purakkattle Biju, Lei Chen, Joshua Close, Peter H. Fuller, Xianhai Huang, Min K. Park, Valdimir Simov, David J. Witter, Hongjun Zhang
  • SUBSTITUTED INDAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
    Publication number: 20190276438
    Abstract: The present invention relates to compounds according to Formula I and pharmaceutically acceptable salts thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or conditions.
    Type: Application
    Filed: March 18, 2019
    Publication date: September 12, 2019
    Inventors: Blair T. Lapointe, Peter H. Fuller, Hakan Gunaydin, Kun Liu, Mark E. Scott, B. Wesley Trotter, Hongjun Zhang
  • Substituted bicyclic pyrazole compounds as RORgammaT inhibitors and uses thereof
    Patent number: 10344000
    Abstract: The present invention relates to compounds according to Formula I: and pharmaceutically acceptable salts thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or conditions.
    Type: Grant
    Filed: October 27, 2016
    Date of Patent: July 9, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Blair T. Lapointe, Peter H. Fuller, Hakan Gunaydin, Kun Liu, Danielle F. Molinari, Qinglin Pu, Mark E. Scott, B. Wesley Trotter, Hongjun Zhang
  • Positron emission tomography imaging system
    Patent number: 10345460
    Abstract: The present disclosure relates to systems and methods for heat transfer and cooling in PET. The system may include a gantry including a gantry forming a detection tunnel; a detector mounted to the gantry, and positioned in a circumference of the detection tunnel; a heat transfer device thermally coupled with the detector and configured to transfer heat generated by the detector; and a cooling device thermally coupled to the heat transfer device, and configured to cool the heat transfer device.
    Type: Grant
    Filed: August 31, 2017
    Date of Patent: July 9, 2019
    Assignee: SHANGHAI UNITED IMAGING HEALTHCARE CO., LTD.
    Inventors: Hao Yan, Wei Zhang, Huawei Jiang, Shigang Su, Miao Li, Hongjun Zhang, Weiping Liu
  • HETEROARYL SUBSTITUTED BENZOIC ACIDS AS RORgammaT INHIBITORS AND USES THEREOF
    Publication number: 20190194186
    Abstract: The present invention relates to compounds according to Formula I and pharmaceutically acceptable salts thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or conditions.
    Type: Application
    Filed: October 27, 2016
    Publication date: June 27, 2019
    Inventors: Hongjun Zhang, Kenneth Jay Barr, Blair T. Lapointe, Hakan Gunaydin, Kun Liu, B. Wesley Trotter
  • NOVEL SUBSTITUTED BIARYL COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS
    Publication number: 20190144433
    Abstract: Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: Also disclosed herein are uses of a compound disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of a composition in the potential treatment or prevention of an IDO-associated disease or disorder.
    Type: Application
    Filed: November 12, 2018
    Publication date: May 16, 2019
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Yongxin Han, Abdelghani Achab, Yongqi Deng, Xavier Fradera, Craig Gibeau, Brett A. Hopkins, Derun Li, Kun Liu, Meredeth A. McGowan, Nunzio Sciammetta, David Sloman, Catherine White, Hongjun Zhang, Hua Zhou
  • Substituted indazole compounds as RORgammaT inhibitors and uses thereof
    Patent number: 10287272
    Abstract: The present invention relates to compounds according to Formula (I) and pharmaceutically acceptable salts thereof. Such compounds can be used in the treatment o RORgammaT-mediated diseases or conditions.
    Type: Grant
    Filed: October 27, 2016
    Date of Patent: May 14, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Blair T. Lapointe, Peter H. Fuller, Hakan Gunaydin, Kun Liu, Mark E. Scott, B. Wesley Trotter, Hongjun Zhang
  • Substituted pyrazole compounds as RORgammaT inhibitors and uses thereof
    Patent number: 10221142
    Abstract: The present invention relates to compounds according to Formula (I-1) and pharmaceutically acceptable salts thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or conditions.
    Type: Grant
    Filed: February 11, 2016
    Date of Patent: March 5, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Blair T. Lapointe, Peter H. Fuller, Hakan Gunaydin, Kun Liu, Nunzio Sciammetta, Benjamin Wesley Trotter, Hongjun Zhang, Kenneth J. Barr, John K. F. Maclean, Danielle F. Molinari, Vladimir Simov
  • 4-heteroaryl substituted benzoic acid compounds as RORgammaT inhibitors and uses thereof
    Patent number: 10196354
    Abstract: The present invention relates to compounds according to Formula I (Formula I), and pharmaceutically acceptable salts or solvates thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or conditions.
    Type: Grant
    Filed: July 12, 2017
    Date of Patent: February 5, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Kenneth J. Barr, Corey E. Bienstock, John K. Maclean, Hongjun Zhang, Richard T. Beresis, Dongshan Zhang, Neville J. Anthony, Blair T. Lapointe, Yuan Tian
  • NOVEL COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS
    Publication number: 20180362482
    Abstract: Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.
    Type: Application
    Filed: December 12, 2016
    Publication date: December 20, 2018
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Yongxin Han, Abdelghani Achab, Purakkattle Biju, Yongqi Deng, Xavier Fradera, Liangqin Guo, Shuwen He, Joseph Kozlowski, Ravi Kurukulasuriya, Kun Liu, Meredeth Ann McGowan, Qinglin Pu, Nunzio Sciammetta, Hongjun Zhang, Hua Zhou
  • SUBSTITUTED INDAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
    Publication number: 20180312489
    Abstract: The present invention relates to compounds according to Formula (I) and pharmaceutically acceptable salts thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or conditions.
    Type: Application
    Filed: October 27, 2016
    Publication date: November 1, 2018
    Inventors: Blair T. Lapointe, Peter H. Fuller, Hakan Gunaydin, Kun Liu, Mark E. Scott, B. Wesley Trotter, Hongjun Zhang
  • SUBSTITUTED BICYCLIC PYRAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
    Publication number: 20180305320
    Abstract: The present invention relates to compounds according to Formula I: and pharmaceutically acceptable salts thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or conditions.
    Type: Application
    Filed: October 27, 2016
    Publication date: October 25, 2018
    Inventors: Blair T. Lapointe, Peter H. Fuller, Hakan Gunaydin, Kun Liu, Danielle F. Molinari, Qinglin Pu, Mark E. Scott, B. Wesley Trotter, Hongjun Zhang
  • POSITRON EMISSION TOMOGRAPHY IMAGING SYSTEM
    Publication number: 20180231673
    Abstract: The present disclosure relates to systems and methods for heat transfer and cooling in PET. The system may include a gantry including a gantry forming a detection tunnel; a detector mounted to the gantry, and positioned in a circumference of the detection tunnel; a heat transfer device thermally coupled with the detector and configured to transfer heat generated by the detector; and a cooling device thermally coupled to the heat transfer device, and configured to cool the heat transfer device.
    Type: Application
    Filed: August 31, 2017
    Publication date: August 16, 2018
    Applicant: SHANGHAI UNITED IMAGING HEALTHCARE CO., LTD.
    Inventors: Hao YAN, Wei ZHANG, Huawei JIANG, Shigang SU, Miao LI, Hongjun ZHANG, Weiping LIU
  • APPARATUS, SYSTEM AND METHOD FOR RADIATION BASED IMAGING
    Publication number: 20180199898
    Abstract: A system and method relating to a radiation based imaging are provided. The system may include a radiation source, a detector and a first grid. The detector may include a plurality of detector cells. The first grid may be located between the radiation source and the detector cells and the first grid may include a plurality of radiation transmitting sections. At least one of the plurality of detector cells may include an active area which may be configured to receive radiation from the radiation source that passes through at least one of the plurality of radiation transmitting sections of the first grid. The active area may be adjustable by adjusting the first grid. The radiation source, the first grid and the detectors cells may be operatively coupled for detecting an object. The method may include adjusting the first grid to adjust the active area of the detector.
    Type: Application
    Filed: December 25, 2015
    Publication date: July 19, 2018
    Applicant: SHANGHAI UNITED IMAGING HEALTHCARE CO., LTD.
    Inventor: Hongjun ZHANG
  • RORgammaT inhibitors
    Patent number: 9884043
    Abstract: The present invention relates to compounds according to Formula (I) or a pharmaceutically acceptable salt or solvate thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or condition.
    Type: Grant
    Filed: March 20, 2017
    Date of Patent: February 6, 2018
    Assignees: Merck Sharp & Dohme Corp., Merck Sharp & Dohme B.V.
    Inventors: Willem Frederik Johan Karstens, Mario Van Der Stelt, Jos Cals, Rita Corte Real Goncalves Azevedo, Kenneth Jay Barr, Hongjun Zhang, Richard Thomas Beresis, Dongshan Zhang, Xiaobang Duan
  • 4-HETEROARYL SUBSTITUTED BENZOIC ACID COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
    Publication number: 20180022701
    Abstract: The present invention relates to compounds according to Formula I (Formula I), and pharmaceutically acceptable salts or solvates thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or conditions.
    Type: Application
    Filed: July 12, 2017
    Publication date: January 25, 2018
    Inventors: Kenneth J. Barr, Corey E. Bienstock, John K. Maclean, Hongjun Zhang, Richard T. Beresis, Dongshan Zhang, Neville J. Anthony, Blair T. Lapointe, Yuan Tian
  • SUBSTITUTED PYRAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
    Publication number: 20180016239
    Abstract: The present invention relates to compounds according to Formula (I-1) and pharmaceutically acceptable salts thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or conditions.
    Type: Application
    Filed: February 11, 2016
    Publication date: January 18, 2018
    Inventors: Blair T. Lapointe, Peter H. Fuller, Hakan Gunaydin, Kun Liu, Nunzio Sciammetta, Benjamin Wesley Trotter, Hongjun Zhang, Kenneth J. Barr, John K. F. Maclean, Danielle F. Molinari, Vladimir Simov
  • RORgammaT INHIBITORS
    Publication number: 20170340610
    Abstract: The present invention relates to compounds according to Formula (I) or a pharmaceutically acceptable salt or solvate thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or condition.
    Type: Application
    Filed: March 20, 2017
    Publication date: November 30, 2017
    Inventors: Willem Frederik Johan Karstens, Mario Van Der Stelt, Jos Cals, Rita Corte Real Goncalves, Kenneth Jay Barr, Hongjun Zhang, Richard Thomas Beresis, Dongshan Zhang, Xiaobang Duan